This Year’s Press Releases

Press Release: Sanofi’s half-year financial report for 2026

Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded

Press Release: Sanofi announces decision not to submit amlitelimab in atopic dermatitis for global regulatory reviews

Press Release: Sanofi evolves its Executive Committee to support its next strategic chapter

Press Release: Sanofi’s subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered via on-body injector

Press Release: Availability of the aide-mémoire for Q2 2026 results

Press Release: Sanofi’s Nexviazyme met all primary and secondary endpoints in infantile-onset Pompe disease phase 3 study

Press Release: Sanofi Foundation opens new chapter centered on future generations

Press Release: Sanofi’s Wayrilz approved in Japan to treat immune thrombocytopenia

Press Release: Sanofi’s Cenrifki (tolebrutinib) approved in the EU as the first disability-targeting medicine for secondary progressive multiple sclerosis without relapses

Press Release: Sanofi appoints Paulo Fontoura as Global Head of R&D

Press Release: Sanofi’s Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma

Communiqué de presse : Sanofi et HEC Paris lancent la « Sanofi MBA Life Sciences Scholarship » pour accompagner les futurs leaders de la santé

Press Release: Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes

Press Release: Sanofi provides update on MOBILIZE phase 3 study of riliprubart in chronic inflammatory demyelinating polyneuropathy

Press Release: Sanofi’s Sarclisa subcutaneous approved in the EU as the first anticancer treatment administered via an on-body injector

Press Release: Sanofi launches 2026 global employee stock purchase plan

Communiqué de presse : Sanofi fédère l'écosystème de santé pour accélérer le diagnostic des maladies rares en France : Biogen rejoint accelRare

Press Release: Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher disease

Press Release: ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD